Hyperammonemia

05/01/2001 - "An improved understanding of the metabolism of ammonia and neurological consequences of hyperammonemia will assist the nephrologist in providing optimal care for this high-risk patient population."
04/28/2015 - "In conclusion, the present observations highlight the importance of hepatic GS for maintenance of ammonia homeostasis and establish the liver-specific GS KO mouse as a model with which to study effects of chronic hyperammonemia. "
03/01/2014 - "Our work attempts to reproduce an increase in rat cerebral ammonia level, study the hyperamonemic animals' performance of two learning tasks, an allocentric (ALLO) and a cue guided (CG) task, and elucidate the contribution of hyperammonemia to the differential energy requirements of the brain limbic system regions involved in these tasks. "
10/01/2008 - "In this study, we aimed to modulate hyperammonemia in three rodent models by administration of wild-type Lactobacillus plantarum, a genetically engineered ammonia hyperconsuming strain, and a strain deficient for the ammonia transporter. "
07/01/1996 - "Because dialysis has been recommended for acute hyperammonemia in other conditions, we have conducted a study to analyze the determinants of ammonia clearance with the use of a single-pass dialyzer. "

09/01/2000 - "Sodium benzoate (SB) therapy has been beneficial in the treatment of hyperammonemia. "
05/01/1983 - "Although sodium benzoate offers considerable promise for the treatment of hyperammonemia, toxicity appears likely in some infants receiving this drug in currently recommended doses. "
12/01/1989 - "It is recommended that methylsuccinate-free sodium benzoate should be used for the treatment of hyperammonemia."
12/01/1989 - "Of the two unusual substances, methylsuccinate was found to be a contaminant of sodium benzoate administered for the treatment of hyperammonemia. "
10/01/1988 - "Our results warrant a reevaluation of the use of sodium benzoate in the treatment of hyperammonemia."

05/01/2005 - "To investigate the incidences of urea cycle defects (UCDs) in the patients with hyperammonemia and study their etiology, clinical and laboratory features. "
03/01/1984 - "Subsequent studies showed that consumption of an Arg-free diet resulted in growth failure, emetic episodes, mild hyperammonemia, decreased plasma Arg and urea, and orotic aciduria. "
09/01/2013 - "Mitochondrial dysfunction impairs urea production and result in hyperammonemia (Semin Neonatol 2002;7:27). "
08/15/2013 - "If however the function of the urea cycle is inhibited by toxic metabolites or by substrate deficiencies, the situation is described as secondary hyperammonemia. "
07/01/2013 - "Hyperammonemia can be caused by various acquired or inherited disorders such as urea cycle defects. "

01/01/2011 - "Open questions remain which concern the optimal dosage in acute and long-term use of N-carbamyl-L-glutamate and potential additional disorders in which the drug might also be effective in treating acute hyperammonemia. "
01/01/2011 - "This review focuses on the role of N-carbamyl-L-glutamate for the treatment of acute hyperammonemia due to primary NAGS deficiency but will briefly discuss the current knowledge on the role of N-carbamyl-L-glutamate for treatment of secondary NAGS deficiencies."
07/01/2009 - "Impairment of astrocytic glutamate uptake is another important feature of HE and hyperammonemia. "
08/01/2005 - "Neonatal hyperammonemia: the N-carbamoyl-L-glutamic acid test."
08/01/2002 - "Hyperammonemia could induce the formation of inducible NOS in astroglial cells, with the consequent NO formation, deactivation of GS and dawn-regulation of glutamate uptake. "

09/01/2009 - "This study aimed to evaluate the risk frequency of hyperammonemia and abnormal carnitine levels in children receiving VPA who were otherwise free of neurological or obvious nutritional problems. "
09/01/2015 - "Improvement of hyperammonemia and carnitine deficiency in this group may be related to mitochondrial function."
11/01/2013 - "Supplemental L-carnitine is needed in patients receiving an enteral diet free of carnitine, those with combination therapy of VPA and PB under oral feeding conditions, and those who develop hyperammonemia during VPA therapy. "
04/01/2013 - "A serum carnitine profile was obtained at the time of hyperammonemia and was found to be normal (results were available postdischarge). "
01/01/2012 - "A lack of carnitine is thought to contribute to hyperammonemia. "

01/01/1980 - "At this level hyperammonemia may result from overtreatment, but this can be quickly cleared by a small dose of arginine. "
04/01/1985 - "Therefore, selected animals fed an arginine-deficient diet may serve as a useful model for the study of chronic hyperammonemia. "
01/01/2015 - "Arginine deficiency will result in hyperammonemia, which may be fatal. "
09/01/2006 - "Arginine treatment is able to reduces attacks of hyperammonemia in boys with late-onset OTCD and to increase their growth."
08/01/2004 - "A significant nutritional problem in preterm infants is a severe deficiency of arginine (hypoargininemia), which results in hyperammonemia, as well as cardiovascular, pulmonary, neurological, and intestinal dysfunction. "

10/01/2005 - "Hyperammonemia is known to cause poorly understood perturbations of the citrulline-NO cycle. "
07/01/2000 - "Blood examination showed hyperammonemia, and plasma amino acid analysis revealed a marked increase in the citrulline level. "
09/16/2014 - "The major clinical manifestations were feeding difficulties, persistent vomiting, convulsions, unconsciousness and hyperammonemia, etc. The blood levels of citrulline in these patients were significantly lower than those of the control group (6.35 (1.84-21.11) vs 13.65 (10.23-24.52) µmol/L, P < 0.05) . "
01/01/1984 - "The present study suggests that an oral supplement of arginine or citrulline is effective for preventing postprandial hyperammonemia in this disorder."
07/01/2003 - "Mealtime supplements of citrulline, another urea cycle intermediate that uses other transport mechanisms, prevent postprandial hyperammonemia and improve protein tolerance. "

09/01/1981 - "The hyperammonemia improved somewhat when protein was not given, and it resolved on discontinuation of the valproic acid. "
04/01/2015 - "Hyperammonemia is infrequent adverse affect of treatment with divalproex sodium. "
01/01/2015 - "Valproate-Related Hyperammonemia in Older Adult Psychiatric Inpatients."
09/01/2014 - "Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy. "
07/01/2014 - "Valproate induced hyperammonemia (VIH) is one such side-effect. "

11/01/2015 - "The disease is characterized by neonatal onset of severe encephalopathy, low levels of glutamine in blood and cerebrospinal fluid, chronic moderate hyperammonemia, and an overall poor prognosis in the absence of an effective treatment. "
10/01/2015 - "Massive catabolism and exogenous glutamine administration may have contributed to hyperammonemia and hyperglutaminemia in this patient. "
04/01/2012 - "Cerebral glutamine metabolism under hyperammonemia determined in vivo by localized (1)H and (15)N NMR spectroscopy."
11/01/2011 - "It is now generally accepted that hyperammonemia leads to toxic levels of glutamine in astrocytes. "
10/01/2010 - "In the brain, glutamine synthesis is largely confined to astrocytes, and it is generally accepted that in hyperammonemia excess glutamine compromises astrocyte morphology and function. "

07/01/1987 - "During the 2-year interval of the study, the ornithine HCl supplements were withdrawn on 2 occasions, and within a week the hyperammonemia recurred. "
11/01/2013 - "Successful continuous venovenous hemofiltration in a neonate with hyperammonemia from ornithine transcabamylase deficiency."
06/01/2010 - "In conditional ornithine deficiency, daily supplementation with LOLA at doses about 1 g/day is safe and, as demonstrated in vitro, should be sufficient to saturate tissue ornithine concentration to prevent postprandial hyperammonemia and to stimulate tissue regeneration."
12/01/2007 - "Ornithine supplementation restored ureagenesis and mitigated hyperammonemia. "
09/01/2006 - "Although most human AI-deficient patients have no symptomatic hyperammonemia at birth, it is possible that clinically significant ornithine deficiency is already present."

06/01/2013 - "In addition, 20 rats were given serial oral administrations of 10% NH4Cl solution (10 ml/kg, every 8 hrs) to establish the hyperammonemia-induced liver injury model; an additional 20 rats were prepared in parallel to serve as the ALF control group (n = 10; D-galactosamine at 800 mg/kg every 6 d for 30 days) and the physiological saline control group (n = 10). "
02/01/2004 - "Hyperammonemia was induced by oral administration of an amino-acid (aa) solution mimicking hemoglobin composition. "
01/01/1995 - "She suffered a consciousness disturbance due to hyperammonemia, which was successfully treated by oral administration of sodium benzoate before surgery. "
10/01/1992 - "Acute, oral administration of 14.3 to 37.5 mg/kg magnesium valproate (peak serum concentrations, 65 to 139 micrograms/ml) increases spike-wave frequency at 2, 3, 4, and 5 hours postdrug, in the absence of hyperammonemia or significant correlations with ammonemia fluctuations. "
11/01/1982 - "After oral administration of D,L-carnitine (50 mg/kg/day) for four weeks, both carnitine deficiency and hyperammonemia were corrected."

03/01/2015 - "This study adds to the understanding of chemotherapy-induced hyperammonemia as drug-induced CPS1 deficiency is suggested. "
03/01/2015 - "We therefore hypothesized that the acute onset of hyperammonemia was due to an acquired, chemotherapy-induced (posttranscriptional) CPS1 deficiency. "
08/01/2014 - "Pharmacotherapy for hyperammonemia."
08/01/2014 - "Hyperammonemia, resolved by chemotherapy."
01/01/2010 - "The patient developed acute idiopathic hyperammonemia after 5 days of chemotherapy and died 9 days after chemotherapy. "

11/01/2013 - "This study aimed to investigate the clinical effect of transplantation of CD133⁺ peripheral blood stem cells or umbilical cord mesenchymal stem cells via the hepatic artery in children with type II hyperammonemia and its possible action mechanism. "
01/01/2014 - "We describe three lung transplant recipients who developed acute hyperammonemia early after transplantation. "
03/01/2013 - "After transplantation, there were no episodes of hyperammonemia. "
07/01/2008 - "We describe the successful management of a lung transplant recipient with severe hyperammonemia."
05/27/2001 - "Hyperammonemia alleviated in the patient after the transplantation, thereby dramatically improving her quality of life. "

05/01/1995 - "The overall results indicate that CAVHD should be considered for hyperammonemia when peritoneal dialysis is indicated but unfeasible or inefficient."
01/01/1985 - "In view of the possibility of this and other complications of peritoneal dialysis, pharmacologic therapy of neonatal hyperammonemia should be considered as an initial modality of treatment."
06/01/1995 - "Hyperammonemic encephalopathy was controlled with medical therapy in case 1 until the of 5 years, but the complicated course in case 2 in which hyperammonemia required peritoneal dialysis and hemodialysis in the neonatal period necessitated OLTx with a reduced-size liver at the age of 80 days. "
07/01/1979 - "Comparison of exchange transfusion, peritoneal dialysis, and hemodialysis for the treatment of hyperammonemia in an anuric newborn infant."
01/01/2008 - "Our results demonstrate that peritoneal dialysis may still be an effective treatment for neonatal hyperammonemia caused by inborn errors of metabolism. "

04/01/2015 - "One patient experienced improvement in the hyperammonemia after surgical correction of spontaneous splenorenal shunt. "
07/07/2014 - "After an extensive workup, he was found to have hyperammonemia and encephalopathy due to formation of a spontaneous splenorenal shunt. "
07/07/2014 - "Novel therapy for non-cirrhotic hyperammonemia due to a spontaneous splenorenal shunt."
11/01/2000 - "The cumulative rates of hyperammonemia at 5 and 10 years were significantly higher in the distal splenorenal shunt group (30.4%, 30.4%) than in the esophageal transection group (0%, 5.6%) (P = 0.009). "
05/01/2000 - "Distal splenorenal shunt with splenopancreatic disconnection and gastric transection may reduce the incidence of postoperative hyperammonemia."